Cannabis
Pure Global Receives Oils Sales License from Health Canada
Pure Global Cannabis Inc. (TSX.V: PURE; OTC: PRCNF; FRA: 1QS) (“Pure Global” or “PURE“) an integrated, growth-oriented life sciences and consumer products cannabis company, through its wholly-owned subsidiary PureSinse Inc. (“PureSinse” or the “Company“), a Health Canada licensed producer under The Cannabis Act, is pleased to announce that it has received approval from Health Canada for its most recent license amendment request allowing for the sale of cannabis oil products, including high cannabidiol (“CBD”) and premium craft cultivars that will become available soon for medical and legal adult patients.
This licensing will allow the Company to significantly expand its product offerings to the medical and consumer markets with oils and post-derivative cannabis products, which are seeing growing demand. Oils and post-derivatives will be deployed throughout the Company’s brand ecosystem, especially as edibles and post-derivative products regulations come into being this fall. This will enable the company to significantly expand consumer sales through higher margin products.
The Company already has prepared oils formulations, as well as purification, processing, and packaging equipment in place for this next phase of operations. It has the capacity to purify, formulate, and process 10 liters of oil per day, 10,000 capsules per hour, 10,000 vape cartridges per hour, and 2,000 oils bottles per hour. With Health Canada approval for oil sales, the Company can release its line of extraction-based products which will soon be available through its PureSinse Medical eCommerce site, as well as legal retail cannabis stores across Canada. Pure Global had already expanded production capabilities, anticipating license approval, to include in-house production of medicated topicals, creams, gels, balms, lotions, tinctures, sprays, vape pens, oils bottles, and gel capsules.
This licensing also clears the path for Health Canada approvals for Phase 2 cultivation and extraction, for which the Company has already submitted its readiness package and is in final stages of approvals. With over 80 genetics to choose from, the company is ready to begin vertically farmed cultivation and scaled extraction for its branded and for white labeled products.
“This is an important milestone in our company’s history which will significantly expand our product offerings for the medical and legal adult channels. We will be able to sell high-margin oils and post-derivative products across all of our premium brands and will be one of only and handful of Licensed Producers to be able to do so. Over 50% of medical patients are looking for post-derivative products as well as those in our target consumer markets, which we will now be much better able to serve,” commented Malay Panchal, President and CEO of Pure Global.
SOURCE Pure Global Cannabis Inc.
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis5 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis5 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis4 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis3 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis3 days ago
Rubicon Organics Reports Q1 2024 Financial Results